Zacks Investment Research downgraded shares of Sartorius (OTCMKTS:SARTF) from a hold rating to a sell rating in a report published on Tuesday.

According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “

Shares of Sartorius stock opened at $109.50 on Tuesday. Sartorius has a 52 week low of $109.50 and a 52 week high of $149.00. The company has a current ratio of 1.62, a quick ratio of 1.00 and a debt-to-equity ratio of 1.08.

Sartorius (OTCMKTS:SARTF) last announced its quarterly earnings results on Tuesday, October 23rd. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. The company had revenue of $459.56 million for the quarter, compared to analyst estimates of $460.00 million. Sartorius had a net margin of 9.09% and a return on equity of 20.21%. Research analysts predict that Sartorius will post 2.98 earnings per share for the current year.

Sartorius Company Profile

There is no company description available for Sartorius AG.

See Also: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on Sartorius (SARTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.